Ipsen Biopharmaceuticals Canada Inc. Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Children Aged Two and Older

Approval is based on the first large-scale neurotoxin trial to demonstrate meaningful functional improvement in pediatric lower limb spasticity

The Ipsen Biopharmaceuticals Canada Inc., the Canadian affiliate of Ipsen (EURONEXT PARIS: IPN) (ADR: IPSEY) today announced that Health Canada has approved DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients two years of age and older.

Click here for the press release.